Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 16.23
(-0.55%)
CNY 16.23
(-0.55%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 758.92 Million CNY | 272.73% |
| 2022 | 203.61 Million CNY | 1665.73% |
| 2021 | 11.53 Million CNY | 118.35% |
| 2020 | -62.85 Million CNY | -4187.04% |
| 2019 | -1.46 Million CNY | 96.28% |
| 2018 | -39.36 Million CNY | -161.78% |
| 2017 | 63.71 Million CNY | -61.65% |
| 2016 | 166.13 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 1.21 Billion CNY | -15.93% |
| 2024 Q2 | 1.06 Billion CNY | 2.99% |
| 2024 Q1 | 1.03 Billion CNY | 36.51% |
| 2023 Q3 | 933.12 Million CNY | 27.37% |
| 2023 Q2 | 732.62 Million CNY | 60.59% |
| 2023 FY | 758.92 Million CNY | 272.73% |
| 2023 Q1 | 456.2 Million CNY | 124.06% |
| 2023 Q4 | 758.92 Million CNY | -18.67% |
| 2022 Q4 | 203.61 Million CNY | -39.58% |
| 2022 Q3 | 336.99 Million CNY | 3.52% |
| 2022 Q2 | 325.54 Million CNY | 61.32% |
| 2022 Q1 | 201.8 Million CNY | 1650.03% |
| 2022 FY | 203.61 Million CNY | 1665.73% |
| 2021 Q1 | 58.26 Million CNY | 192.69% |
| 2021 Q4 | 11.53 Million CNY | -92.35% |
| 2021 FY | 11.53 Million CNY | 118.35% |
| 2021 Q2 | 23.69 Million CNY | -59.33% |
| 2021 Q3 | 150.77 Million CNY | 536.36% |
| 2020 Q2 | 162.95 Million CNY | -4.56% |
| 2020 Q4 | -62.85 Million CNY | -163.35% |
| 2020 FY | -62.85 Million CNY | -4187.04% |
| 2020 Q3 | 99.21 Million CNY | -39.12% |
| 2020 Q1 | 170.74 Million CNY | 11745.29% |
| 2019 Q2 | -6.17 Million CNY | -103.4% |
| 2019 FY | -1.46 Million CNY | 96.28% |
| 2019 Q1 | 181.46 Million CNY | 0.0% |
| 2019 Q4 | -1.46 Million CNY | 0.0% |
| 2018 FY | -39.36 Million CNY | -161.78% |
| 2017 FY | 63.71 Million CNY | -61.65% |
| 2016 FY | 166.13 Million CNY | 0.0% |